for people ages up to 9 months (full criteria)
at San Francisco, California and other locations
study started
completion around



This is a multi-center, prospective, parallel-group, open-label, randomized clinical study in one hundred and twenty-six (126) neonates and infants diagnosed with CH.

Subjects will be randomized in a 2:1 ratio to Treatment (Tirosint®-SOL) or Control (conventional therapy with levothyroxine sodium crushed tablets).

Official Title

A Randomized Comparative Study Between Liquid (Tirosint®-SOL) and Tablet Formulations of Levothyroxine in Neonates and Infants With Congenital Hypothyroidism


Newly diagnosed neonates will be randomly assigned to start therapy with LT4 at the initial dose recommended by the Standard of Care (SOC). Infants already on LT4 therapy will continue at the same daily dose within the randomly assigned treatment group (dose adjustments are allowed, if needed based on laboratory parameters and clinical response). Once enrolled, subjects will be treated and followed for 12 months (±1.5 months), participating in 7-8 study visits, consisting of 6-7 inclinic and 1-2 (or more if follow-up visits are required) telemedicine (TM) visits. The total number of visits depends on the age at inclusion.


Congenital Hypothyroidism, Hypothyroidism, Tirosint®-SOL, Levothyroxine Sodium


You can join if…

Open to people ages up to 9 months

  • Male and female patient aged 0 to 9 months
  • Primary CH diagnosis with elevated TSH and low T4, requiring treatment with LT4, under either of the following conditions:
    • Neonates newly diagnosed with primary CH and needing to initiate LT4 therapy, or
    • Infants previously diagnosed with primary CH and who are already on LT4 therapy for at least 4 weeks;
  • Provide and comply with the informed consent.

You CAN'T join if...

  • Preterm neonates with a gestational age < 37 weeks;
  • Low birth weight and very low birth weight neonates (weight < 2.5 kg);
  • Neonates in neonatal intensive care units or requiring admission to NICU or neonates/infants hospitalized or requiring hospitalization;
  • CH diagnosis > 4 weeks after delivery (for newly diagnosed neonates only);
  • Diagnosis of primary gastrointestinal disease:
    • Gastroesophageal reflux requiring medical therapy (beyond thickening of formula or position);
    • Anatomic defects (e.g. intestinal atresia, malrotation, tracheoesophageal fistula, pyloric stenosis, Hirschsprung's disease, gastroschisis);
    • Dietary allergy (e.g. cow's milk protein allergy);
    • Malabsorption related to cystic fibrosis, celiac disease and others;
    • Necrotizing enterocolitis requiring surgical resection;
  • Known or suspected adrenal insufficiency (e.g. congenital adrenal hyperplasia, hypopituitarism);
  • Diagnosis of congenital cardiac disease, cardiac insufficiency or risk for cardiac failure;
  • Diagnosis of chromosomopathy;
  • Diagnosis of central hypothyroidism;
  • Hypersensitivity to glycerol;
  • Concomitant anticonvulsant medications, liothyronine, combination of LT4 and liothyronine, thyroid extracts and/or chronic or long-term use of systemic glucocorticoids
  • History of nonadherence with medication or medical visit schedule; or
  • Any condition for which, participation would not be in the best interest of the patient or that could limit protocol specified assessments.


  • UCSF accepting new patients
    San Francisco California 94143 United States
  • Children's Hospital of Los Angeles accepting new patients
    Los Angeles California 90027 United States


accepting new patients
Start Date
Completion Date
IBSA Institut Biochimique SA
Phase 4 Hypothyroidism Research Study
Study Type
Expecting 126 study participants
Last Updated